Wire · opportunities
Hims & Hers inks deal with Eli Lilly to offer branded weight loss drugs
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 6 November 2026 · Fusion42 review
Hims & Hers has partnered with Eli Lilly to offer FDA-approved branded GLP-1 weight loss drugs directly on its platform, expanding patient access to injectable and oral obesity treatments with self-pay pricing. This deal follows Hims & Hers' strategic pivot from compounded to branded GLP-1 drugs amid financial pressures and mirrors a similar partnership with Novo Nordisk.
This Wire brief sits within Fusion42's coverage of Healthtech Infrastructure, and 5 sources have reported it between 6 Nov 2026 and 8 Nov 2026.
◆ ◆ The Wire takeaway
Your telehealth platform just became a direct channel for top obesity drugs with this deal. You need to cut out middlemen and integrate branded treatments now or lose patients to platforms offering direct prescription fulfilment.
◆ Coverage
5 sources · first reported 6 Nov 2026 · latest 8 Nov 2026
◆ Related on Wire
◆ Topics